WHO Obesity and overweight fact sheet 311-updated June 2016.
Anderson JW, Konz EC, Frederich RC, Wood CL. Long-term weight-loss maintenance: a meta-analysis of US studies. Am J Clin Nutr 2001; 74: 579–584.
Kraschnewski JL, Boan J, Esposito J, Sherwood NE, Lehman EB, Kephart DK et al. Long-term weight loss maintenance in the United States. Int J Obes (Lond) 2010; 34: 1644–1654.
Sumithran P, Prendergast LA, Delbridge E, Purcell K, Shulkes A, Kriketos A et al. Long-term persistence of hormonal adaptations to weight loss. N Engl J Med 2011; 365: 1597–1604.
Fothergill E, Guo J, Howard L, Kerns JC, Knuth ND, Brychta R et al. Persistent metabolic adaptation 6 years after ‘The Biggest Loser’ competition. Obesity 2016; 24: 1612–1619.
Khera R, Murad MH, Chandar AK, Dulai PS, Wang Z, Prokop LJ et al. Association of pharmacological treatments for obesity with weight loss and adverse events. JAMA 2016; 315: 2424–2434.
Mason EE. History of obesity surgery. Surg Obes Relat Dis 2005; 1: 123–125.
Buchwald H, Schone JL. Gastric obesity surgery combined with partial ileal bypass for hypercholesterolemia. Obes Surg 1997; 7: 313–316.
Buchwald H, Estok R, Fahrbach K, Banel D, Jensen MD, Pories WJ et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med 2009; 122: 248–256.
Gloy VL, Briel M, Bhatt DL, Kashyap SR, Schauer PR, Mingrone G et al. Bariatric surgery versus non-surgical treatment for obesity: a systematic review and meta-analysis of randomised controlled trials. BMJ 2013; 347: f5934.
Schauer PR, Burguera B, Ikramuddin S, Cottam D, Gourash W, Hamad G et al. Effect of laparoscopic Roux-en Y gastric bypass on type 2 diabetes mellitus. Ann Surg 2003; 238: 467–484 discussion 84–85.
Patti ME, McMahon G, Mun EC, Bitton A, Holst JJ, Goldsmith J et al. Severe hypoglycaemia post-gastric bypass requiring partial pancreatectomy: evidence for inappropriate insulin secretion and pancreatic islet hyperplasia. Diabetologia 2005; 48: 2236–2240.
Service GJ, Thompson GB, Service FJ, Andrews JC, Collazo-Cavell ML, Lloyd RV. Hyperinsulinemic hypoglycemia with nesidioblastosis after gastric-bypass surgery. N Engl J Med 2005; 353: 249–254.
Marsk R, Jonas E, Rasmussen F, Näslund E. Nationwide cohort study of post-gastric bypass hypoglycaemia including 5040 patients undergoing surgery for obesity in 1986–2006 in Sweden. Diabetologia 2010; 53: 2307–2311.
Kellogg TA, Bantle JP, Leslie DB, Redmond JB, Slusarek B, Swan T et al. Postgastric bypass hyperinsulinemic hypoglycemia syndrome: characterization and response to a modified diet. Surg Obes Relat Dis 2008; 4: 492–499.
Lee CJ, Wood GC, Lazo M, Brown TT, Clark JM, Still C et al. Risk of post-gastric bypass surgery hypoglycemia in nondiabetic individuals: a single center experience. Obesity 2016; 24: 1342–1348.
Whipple AO, Frantz VK. Adenoma of islet cells with hyperinsulinism: a review. Ann Surg 1935; 101: 1299–1335.
Towler DA, Havlin CE, Craft S, Cryer P. Mechanism of awareness of hypoglycemia. Perception of neurogenic (predominantly cholinergic) rather than neuroglycopenic symptoms. Diabetes 1993; 42: 1791–1798.
Lev-Ran A, Anderson RW. The diagnosis of postprandial hypoglycemia. Diabetes 1981; 30: 996–999.
Salehi M, Gastaldelli A, D’Alessio DA. Altered islet function and insulin clearance cause hyperinsulinemia in gastric bypass patients with symptoms of postprandial hypoglycemia. J Clin Endocrinol Metab 2014; 99: 2008–2017.
Jørgensen NB, Jacobsen SH, Dirksen C, Bojsen-Møller KN, Naver L, Hvolris L et al. Acute and long-term effects of Roux-en-Y gastric bypass on glucose metabolism in subjects with Type 2 diabetes and normal glucose tolerance. Am J Physiol Endocrinol Metab 2012; 303: E122–E131.
Salehi M, Gastaldelli A, D’Alessio DA. Evidence from a single individual that increased plasma GLP-1 and GLP-1-stimulated insulin secretion after gastric bypass are independent of foregut exclusion. Diabetologia 2014; 57: 1495–1499.
Roslin M, Damani T, Oren J, Andrews R, Yatco E, Shah P. Abnormal glucose tolerance testing following gastric bypass demonstrates reactive hypoglycemia. Surg Endosc 2011; 25: 1926–1932.
Kefurt R, Langer FB, Schindler K, Shakeri-Leidenmühler S, Ludvik B, Prager G. Hypoglycemia after Roux-En-Y gastric bypass: detection rates of continuous glucose monitoring (CGM) versus mixed meal test. Surg Obes Relat Dis 2015; 11: 564–569.
Van Beek AP, Emous M, Laville M, Tack J. Dumping syndrome after esophageal, gastric or bariatric surgery: pathophysiology, diagnosis, and management. Obes Rev 2017; 18: 68–85.
Salehi M, Prigeon RL, D’Alessio DA. Gastric bypass surgery enhances glucagon-like peptide 1-stimulated postprandial insulin secretion in humans. Diabetes 2011; 60: 2308–2314.
Sigstad H. A clinical diagnostic index in the diagnosis of the dumping syndrome. Acta Med Scand 2009; 188: 479–486.
Hogan MJ, Service FJ, Sharbrough FW, Gerich JE. Oral glucose tolerance test compared with a mixed meal in the diagnosis of reactive hypoglycemia. A caveat on stimulation. Mayo Clin Proc 1983; 58: 491–496.
Charles MA, Hofeldt F, Shackelford A, Waldeck N, Dodson LE, Bunker D et al. Comparison of oral glucose tolerance tests and mixed meals in patients with apparent idiopathic postabsorptive hypoglycemia: absence of hypoglycemia after meals. Diabetes 1981; 30: 465–470.
Jacobsen SH, Olesen SC, Dirksen C, Jørgensen NB, Bojsen-Møller KN, Kielgast U et al. Changes in gastrointestinal hormone responses, insulin sensitivity, and beta-cell function within 2 weeks after gastric bypass in non-diabetic subjects. Obes Surg 2012; 22: 1084–1096.
Chuang J, Baum L, D’Alessio DA, Salehi M. Glycemic profile assessment using continuous glucose monitoring in patients with and without hypoglyemia after gastric bypass surgery. Diabetes 2012; 61 (Issue Supplement 1).
Mulla CM, Storino A, Yee EU, Lautz D, Sawnhey MS, Moser AJ et al. Insulinoma after bariatric surgery: diagnostic dilemma and therapeutic approaches. Obes Surg 2016; 26: 874–881.
Goh BKP, LLPJ Ooi, Cheow P-C, Tan Y-M, Ong H-S, Chung Y-FA et al. Accurate preoperative localization of insulinomas avoids the need for blind resection and reoperation: analysis of a single institution experience with 17 surgically treated tumors over 19 years. J Gastrointest Surg 2009; 13: 1071–1077.
Reubi JC, Perren A, Rehmann R, Waser B, Christ E, Callery M et al. Glucagon-like peptide-1 (GLP-1) receptors are not overexpressed in pancreatic islets from patients with severe hyperinsulinaemic hypoglycaemia following gastric bypass. Diabetologia 53: 2641–2645.
Salehi M, Gastaldelli A, D’Alessio DA. Blockade of glucagon-like peptide 1 receptor corrects postprandial hypoglycemia after gastric bypass. Gastroenterology 2014; 146: 669–680.
Shah M, Law JH, Micheletto F, Sathananthan M, Dalla Man C, Cobelli C et al. Contribution of endogenous glucagon-like peptide 1 to glucose metabolism after Roux-en-Y gastric bypass. Diabetes 2014; 63: 483–493.
Goldfine AB, Mun EC, Devine E, Bernier R, Baz-Hecht M, Jones DB et al. Patients with neuroglycopenia after gastric bypass surgery have exaggerated incretin and insulin secretory responses to a mixed meal. J Clin Endocrinol Metab 2007; 92: 4678–4685.
Craig CM, Liu L-F, Deacon CF, Holst JJ, McLaughlin TL. Critical role for GLP-1 in symptomatic post-bariatric hypoglycaemia. Diabetologia 2017; 60: 531–540.
Salehi M, Woods SC, D’Alessio DA. Gastric bypass alters both glucose-dependent and glucose-independent regulation of islet hormone secretion. Obesity 2015; 23: 2046–2052.
Abrahamsson N, Börjesson JL, Sundbom M, Wiklund U, Karlsson FA, Eriksson JW. Gastric bypass reduces symptoms and hormonal responses in hypoglycemia. Diabetes 2016; 65: 2667–2675.
Patti ME, Li P, Goldfine AB. Insulin response to oral stimuli and glucose effectiveness increased in neuroglycopenia following gastric bypass. Obesity (Silver Spring) 2015; 23: 798–807.
Botros N, Rijnaarts I, Brandts H, Bleumink G, Janssen I, de Boer H. Effect of carbohydrate restriction in patients with hyperinsulinemic hypoglycemia after Roux-en-Y gastric bypass. Obes Surg 2014; 24: 1850–1855.
Bantle JP, Laine DC, Castle GW, Thomas JW, Hoogwerf BJ, Goetz FC. Postprandial glucose and insulin responses to meals containing different carbohydrates in normal and diabetic subjects. N Engl J Med 1983; 309: 7–12.
Bantle AE, Wang Q, Bantle JP. Post-gastric bypass hyperinsulinemic hypoglycemia: fructose is a carbohydrate which can be safely consumed. J Clin Endocrinol Metab 2015; 100: 3097–3102.
Axelsen M, Wesslau C, Lonnroth P, Lenner RA, Smith U. Bedtime uncooked cornstarch supplement prevents nocturnal hypoglycaemia in intensively treated type 1 diabetes subjects. J Intern Med 1999; 245: 229–236.
Derosa G, Maffioli P. Mini-special issue paper management of diabetic patients with hypoglycemic agents α-glucosidase inhibitors and their use in clinical practice. Arch Med Sci 2012; 5: 899–906.
Valderas JP, Ahuad J, Rubio L, Escalona M, Pollak F, Maiz A. Acarbose improves hypoglycaemia following gastric bypass surgery without increasing glucagon-like peptide 1 levels. Obes Surg 2012; 22: 582–586.
Jenkins DJ, Taylor RH, Goff DV, Fielden H, Misiewicz JJ, Sarson DL et al. Scope and specificity of acarbose in slowing carbohydrate absorption in man. Diabetes 1981; 30: 951–954.
Vezzosi D, Bennet A, Rochaix P, Courbon F, Selves J, Pradere B et al. Octreotide in insulinoma patients: efficacy on hypoglycemia, relationships with octreoscan scintigraphy and immunostaining with anti-sst2A and anti-sst5 antibodies. Eur J Endocrinol 2005; 152: 757–767.
Deloose E, Bisschops R, Holvoet L, Arts J, De Wulf D, Caenepeel P et al. A pilot study of the effects of the somatostatin analog pasireotide in postoperative dumping syndrome. Neurogastroenterol Motil 2014; 26: 803–809.
Myint KS, Greenfield JR, Farooqi IS, Henning E, Holst JJ, Finer N. Prolonged successful therapy for hyperinsulinaemic hypoglycaemia after gastric bypass: the pathophysiological role of GLP1 and its response to a somatostatin analogue. Eur J Endocrinol 2012; 166: 951–955.
Spanakis E, Gragnoli C. Successful medical management of status post-Roux-en-Y-gastric-bypass hyperinsulinemic hypoglycemia. Obes Surg 2009; 19: 1333–1334.
Gonzalez-Gonzalez A, Delgado M, Fraga-Fuentes MD, Singh K, Patel A, Meacham J. Use of diazoxide in management of severe postprandial hypoglycemia in patient after Roux-en-Y gastric bypass. Surg Obes Relat Dis 2010; 9: e18–e19.
Van Boekel G, Loves S, van Sorge A, Ruinemans-Koerts J, Rijnders T, de Boer H. Weight loss in obese men by caloric restriction and high-dose diazoxide–mediated insulin suppression. Diabetes, Obes Metab 2008; 10: 1195–1203.
De Marinis L, Barbarino A. Calcium antagonists and hormone release. I. Effects of verapamil on insulin release in normal subjects and patients with islet-cell tumor. Metabolism 1980; 29: 599–604.
Barbarino A, De Marinis L, Mancini A, Calabrò F, Massari M, D’Amico C et al. Calcium antagonists and hormone release. VI. Effects of a calcium antagonist (verapamil) on the biphasic insulin release in vivo. Diabetes Res 1988; 8: 21–24.
Krempf M, Ranganatan S, Ritz P, Garnier JM, Charbonnel B. Effect of nifedipine on glucose potentiation of the acute insulin response to arginine in non-insulin-dependent diabetics. Eur J Clin Pharmacol 1991; 41: 411–415.
Semple C, Thomson J, Beastall G, Lorimer A. Oral verapamil does not affect glucose tolerance in non-diabetics. Br J Clin Pharmacol 1983; 15: 570–571.
Shamoon H, Baylor P, Kambosos D, Charlap S, Plawes S, Frishman WH. Influence of oral verapamil on glucoregulatory hormones in Man*. J Clin Endocrinol Metab 1985; 60: 536–541.
Moreira RO, Moreira RBM, Machado NAM, Gonçalves TB, Coutinho WF. Post-prandial hypoglycemia after bariatric surgery: pharmacological treatment with verapamil and acarbose. Obes Surg 2008; 18: 1618–1621.
Nath R, Johnson KW, Roessig JM, Ken D, Neale AC RM. XOMA 358, a novel treatment for hyperinsulinemic hypoglycemia: safety and clinical pharmacology from the first in human trial. Endocrine Rev 2015; 36 (Issue 2 Supplement).
Johson K, Johnson KW, Gordon A, Neale AC, Vella A, Lee D et al. Single administration of Xoma 358, an insulin receptor attentuator improves post-meal and nighttime hypoglycemia profiles in post gastric bypass hypoglycemia (PGBH) patients. Endocrine Rev 2017; Vol 38 (Issue 2 Supplement).
Castle JR, Engle JM, Youssef JE, Massoud RG, Yuen KCJ, Kagan R et al. Novel use of glucagon in a closed-loop system for prevention of hypoglycemia in type 1 diabetes. Diabetes Care 2010; 33: 1282–1287.
Mulla C. Automatec event-based system for the prevention of post-bariatric hypoglycemia using a mini-dose of a stable glucagon formulation. Endocrine Rev 2017; 38 (Issue 2 Supplement).
Craig CM. Subcutaneous exendin 9-39 effectively treats post-bariatric hypoglycemia. Diabetes 2016; 65 (Issue Supplement 1).
Mala T. Postprandial hyperinsulinemic hypoglycemia after gastric bypass surgical treatment. Surg Obes Relat Dis 2014; 10: 1220–1225.
Spolverato G, Bhaijee F, Anders R, Salley K, Parambi J, Brown T et al. Total pancreatectomy for the management of refractory post-gastric bypass hypoglycemia. Dig Dis Sci 2015; 60: 1505–1509.
McLaughlin T, Peck M, Holst J, Deacon C. Reversible hyperinsulinemic hypoglycemia after gastric bypass: a consequence of altered nutrient delivery. J Clin Endocrinol Metab 2010; 95: 1851–1855.
Z’graggen K, Guweidhi A, Steffen R, Potoczna N, Biral R, Walther F et al. Severe recurrent hypoglycemia after gastric bypass surgery. Obes Surg 2008; 18: 981–988.
Vanderveen KA, Grant CS, Thompson GB, Farley DR, Richards ML, Vella A et al. Outcomes and quality of life after partial pancreatectomy for noninsulinoma pancreatogenous hypoglycemia from diffuse islet cell disease. Surgery 2010; 148: 1237–1246.